ACHV News and Press, Achieve Life Sciences Inc. From 05/12/22

SEATTLE and VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announ...

AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...

Announcing topline data from its Phase 3 ORCA-2 trial for cytisinicline, the clinical-stage biotech, Achieve Life Sciences (NASDAQ:ACHV) announced on Wednesday that those who received its experimental nicotine addiction therapy were 6-8x were more likley to quit smoking compared to placebo. T...

Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo Primary endpoints demonstrated 6-8x increased odds of smoking abstinence with cytisinicline compared to placebo ...

SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today anno...

We are initiating ACHV with a buy rating and a target price of USD 70. The company is developing a smoking cessation treatment, cytisinicline, with an estimated USD 200-300M peak sales (risk-adjusted). Cytisinicline has completed a phase 3 study, and the top-line data will be rele...

SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today anno...

SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased...

SEATTLE and VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today anno...

Achieve Life Sciences, Inc. (ACHV) Q4 2021 Earnings Conference Call March 10, 2022 04:30 PM ET Company Participants John Bencich - Chief Executive Officer Jerry Wan - Principal Accounting Officer Cindy Jacobs - President & Chief Medical Officer Conference Call Participants Thomas Flaten -...